Braftovi

• Brands Braftovi
• Product Code: Braftovi

• Braftovi (encorafenib) is an oral targeted therapy used to treat adults with cancers that have a specific genetic mutation called BRAF V600E. It belongs to a class of drugs known as BRAF inhibitors, which block the activity of the abnormal BRAF protein that promotes uncontrolled cancer cell growth.

  Indications:

  • Unresectable or metastatic melanoma with BRAF V600E or V600K mutation (in combination with Mektovi [binimetinib], a MEK inhibitor)

  • Metastatic colorectal cancer with BRAF V600E mutation (in combination with Erbitux [cetuximab], an EGFR inhibitor)

  How it works:

  • Braftovi inhibits the mutated BRAF kinase, a protein involved in the MAPK/ERK signaling pathway, which is overactive in certain cancers.

  • Blocking BRAF slows or stops cancer cell growth and may shrink tumors.

  Administration:

  • Oral capsules, taken once daily.

  • Always used in combination with other drugs to improve efficacy and reduce resistance.

  Common side effects:

  • Fatigue

  • Nausea

  • Joint pain

  • Skin rash

  • Abdominal pain

  Serious risks:

  • Risk of new skin cancers (monitoring required)

  • Liver problems

  • Heart rhythm issues (QT prolongation)

  • Eye disorders

  Patients must undergo genetic testing to confirm the presence of a BRAF V600E mutation before starting treatment.

• Availability: In Stock

• American Diabetes Association

• Diabetes Disaster_Response Coalition storing insulin

• FDA Approved Prescription